{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:31:44Z","timestamp":1786480304236,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006591","name":"FibroGen, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006591","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2022,9,29]]},"abstract":"<jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Roxadustat increases hemoglobin and serum iron levels in nondialysis- and dialysis-dependent patients with anemia of CKD.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>As roxadustat improves iron kinetics, less intravenous iron supplementation is required versus placebo or epoetin alfa.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, increases hemoglobin by stimulating erythropoietin synthesis and improving iron availability through facilitation of iron uptake and\/or release from stores. In this exploratory analysis, we assessed the effect of roxadustat treatment on laboratory parameters related to iron metabolism in patients with anemia of chronic kidney disease (CKD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were pooled from pivotal, randomized, phase 3 roxadustat trials: three placebo-controlled, double-blind trials in nondialysis-dependent (NDD) CKD and three open-label, active-comparator (epoetin alfa) trials in dialysis-dependent (DD) CKD. In this exploratory analysis, mean changes from baseline in hemoglobin, iron parameters, and hepcidin, and intravenous (iv) iron use were evaluated. Pooled results in NDD CKD and DD CKD patients are reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 4277 patients with NDD CKD and 3890 patients with DD CKD were evaluated. Hemoglobin increases with roxadustat treatment were accompanied by increases in serum iron and total iron-binding capacity (TIBC) and decreases in serum ferritin and hepcidin from baseline through week 52. With epoetin alfa, the hemoglobin increase was accompanied by decreases in serum ferritin and hepcidin, but serum iron decreased, and there was no change in TIBC. With placebo, there were no changes in hemoglobin, iron parameters, or hepcidin. During treatment, iv iron use was reduced with roxadustat versus placebo and epoetin alfa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with NDD CKD and DD CKD, roxadustat treatment is associated with increases in serum iron and TIBC, accompanied by reduced hepcidin and indicative of improved iron kinetics. Patients treated with roxadustat achieved target hemoglobin levels with less iv iron use versus comparators. Practitioners treating patients with anemia of CKD with roxadustat should consider its unique effects when interpreting iron parameters.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.34067\/kid.0001442022","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T19:05:12Z","timestamp":1656529512000},"page":"1511-1528","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["Changes in Iron Availability with Roxadustat in Nondialysis- and Dialysis-Dependent Patients with Anemia of CKD"],"prefix":"10.34067","volume":"3","clinical-trial-number":[{"clinical-trial-number":"nct02174627","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01887600","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01750190","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02174731","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02273726","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02052310","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5876-894X","authenticated-orcid":false,"given":"Pablo E.","family":"Pergola","sequence":"first","affiliation":[{"name":"Renal Associates PA, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaim","family":"Charytan","sequence":"additional","affiliation":[{"name":"NewYork-Presbyterian Queens, Flushing, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4201-0237","authenticated-orcid":false,"given":"Dustin J.","family":"Little","sequence":"additional","affiliation":[{"name":"Global Medicines Development, Cardiovascular, Renal and Metabolism (CVRM), Biopharmaceuticals Research and Development, AstraZeneca Gaithersburg, Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Tham","sequence":"additional","affiliation":[{"name":"Biostatistics, Cardiovascular, Renal and Metabolism (CVRM), Biopharmaceuticals Research and Development, AstraZeneca Gothenburg, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Szczech","sequence":"additional","affiliation":[{"name":"FibroGen, Inc., San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Leong","sequence":"additional","affiliation":[{"name":"FibroGen, Inc., San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Fishbane","sequence":"additional","affiliation":[{"name":"Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Great Neck, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,9,29]]},"reference":[{"key":"B1-20250825","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B2-20250825","article-title":"KDIGO clinical practice guideline for anemia in chronic kidney disease"},{"key":"B3-20250825","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bjh.12311","article-title":"Guideline for the laboratory diagnosis of functional iron deficiency","volume":"161","author":"Thomas","year":"2013","journal-title":"Br J Haematol"},{"key":"B4-20250825","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1681\/ASN.2019020213","article-title":"Iron deficiency in chronic kidney disease: Updates on pathophysiology, diagnosis, and treatment","volume":"31","author":"Batchelor","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B5-20250825","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s11255-020-02663-z","article-title":"Biomarkers of iron metabolism in chronic kidney disease","volume":"53","author":"Tomasz","year":"2021","journal-title":"Int Urol Nephrol"},{"key":"B6-20250825","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ki.1989.18","article-title":"The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin","volume":"35","author":"Eschbach","year":"1989","journal-title":"Kidney Int"},{"key":"B7-20250825","doi-asserted-by":"crossref","first-page":"8343","DOI":"10.1038\/s41598-021-87401-w","article-title":"Low serum iron is associated with anemia in CKD stage 1\u20134 patients with normal transferrin saturations","volume":"11","author":"Yu","year":"2021","journal-title":"Sci Rep"},{"key":"B8-20250825","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/jpet.120.265181","article-title":"Nonclinical characterization of the hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat, a novel treatment for anemia of chronic kidney disease","volume":"374","author":"Del Balzo","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"B9-20250825","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1093\/nar\/27.21.4223","article-title":"HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation","volume":"27","author":"Bianchi","year":"1999","journal-title":"Nucleic Acids Res"},{"key":"B10-20250825","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cmet.2008.12.012","article-title":"Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency","volume":"9","author":"Shah","year":"2009","journal-title":"Cell Metab"},{"key":"B11-20250825","doi-asserted-by":"crossref","first-page":"20055","DOI":"10.1074\/jbc.272.32.20055","article-title":"Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1","volume":"272","author":"Rolfs","year":"1997","journal-title":"J Biol Chem"},{"key":"B12-20250825","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1097\/HS9.0000000000000035","article-title":"Erythroferrone: An erythroid regulator of hepcidin and iron metabolism","volume":"2","author":"Coffey","year":"2018","journal-title":"HemaSphere"},{"key":"B13-20250825","doi-asserted-by":"crossref","first-page":"e14434","DOI":"10.14814\/phy2.14434","article-title":"Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD)","volume":"8","author":"Noonan","year":"2020","journal-title":"Physiol Rep"},{"key":"B14-20250825","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2014-06-584607","article-title":"Erythroferrone contributes to recovery from anemia of inflammation","volume":"124","author":"Kautz","year":"2014","journal-title":"Blood"},{"key":"B15-20250825","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for anemia in patients with kidney disease not receiving dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"B16-20250825","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"B17-20250825","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1159\/000508100","article-title":"A phase 3, multicenter, randomized, two-arm, open-label study of intermittent oral dosing of roxadustat for the treatment of anemia in Japanese erythropoiesis-stimulating agent-na\u00efve chronic kidney disease patients not on dialysis","volume":"144","author":"Akizawa","year":"2020","journal-title":"Nephron"},{"key":"B18-20250825","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1007\/s12325-019-00943-4","article-title":"Roxadustat treatment of chronic kidney disease\u2013associated anemia in Japanese patients not on dialysis: A phase 2, randomized, double-blind, placebo-controlled trial","volume":"36","author":"Akizawa","year":"2019","journal-title":"Adv Ther"},{"key":"B19-20250825","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2019060623","article-title":"Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan","volume":"31","author":"Akizawa","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B20-20250825","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1681\/ASN.2020081150","article-title":"Roxadustat for treating anemia in patients with CKD not on dialysis: Results from a randomized phase 3 study","volume":"32","author":"Fishbane","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B21-20250825","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ekir.2020.11.034","article-title":"Roxadustat for CKD-related anemia in non-dialysis patients","volume":"6","author":"Coyne","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B22-20250825","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1093\/ndt\/gfab057","article-title":"Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: A phase 3, randomized, double-blind, placebo-controlled study (ALPS)","volume":"36","author":"Shutov","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"B23-20250825","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/ndt\/gfab051","article-title":"Roxadustat for anemia in patients with end-stage renal disease incident to dialysis","volume":"36","author":"Provenzano","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"B24-20250825","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.ekir.2021.04.007","article-title":"A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study","volume":"6","author":"Charytan","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B25-20250825","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/jbmr.4272","article-title":"The HIF-PHI BAY 85-3934 (molidustat) improves anemia and is associated with reduced levels of circulating FGF23 in a CKD mouse model","volume":"36","author":"Noonan","year":"2021","journal-title":"J Bone Mineral Res"},{"key":"B26-20250825","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4161\/cc.7.1.5145","article-title":"Role of the hypoxia inducible factors HIF in iron metabolism","volume":"7","author":"Peyssonnaux","year":"2008","journal-title":"Cell Cycle"},{"key":"B27-20250825","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.kint.2021.03.019","article-title":"Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone","volume":"100","author":"Hanudel","year":"2021","journal-title":"Kidney Int"},{"key":"B28-20250825","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s41100-017-0103-1","article-title":"Timing-adjusted iron dosing enhances erythropoiesis-stimulating agent-induced erythropoiesis response and iron utilization","volume":"3","author":"Kawano","year":"2017","journal-title":"Ren Replace Ther"},{"key":"B29-20250825","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/kisup.2012.34","article-title":"Chapter 2: Use of iron to treat anemia in CKD","volume":"2","year":"2012","journal-title":"Kidney Int Suppl (2011)"},{"key":"B30-20250825","doi-asserted-by":"crossref","first-page":"i9","DOI":"10.1093\/ckj\/sfx100","article-title":"Practical considerations for iron therapy in the management of anaemia in patients with chronic kidney disease","volume":"10","author":"Roger","year":"2017","journal-title":"Clin Kidney J"},{"key":"B31-20250825","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.ackd.2019.05.002","article-title":"Novel oral iron therapies for iron deficiency anemia in chronic kidney disease","volume":"26","author":"Pergola","year":"2019","journal-title":"Adv Chronic Kidney Dis"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0001442022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:02:41Z","timestamp":1786478561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0001442022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,29]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0001442022","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,29]]},"assertion":[{"value":"2022-03-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}